ClinicalTrials.gg
Drug

Camrelizumab clinical trials

Also written SHR-1210 and Carrelizumab.

studies test it
393
open now
146
in phase 3
47
first study started
2015

How each study uses camrelizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the camrelizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Camrelizumab
181
Apatinib
8
Anti-PD-1 Antibody
6
Camrelizumab for Injection
6
Cisplatin
4

Development codes

SHR-1210
106
HR-301210
1

Other names

Carrelizumab
4

In one entry with another drug

Given together, or one or the other

Camrelizumab plus Apatinib
7
Camrelizumab and Apatinib
4
Capecitabine, Camrelizumab
3
Apatinib plus Camrelizumab
2
TACE Plus Camrelizumab and Apatinib
2
Carilizumab and Apatinib
2
Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
2
camrelizumab + famitinib
2

Studies by the year they started

393 studies that test it; most in 2021 (87)

Studies that test camrelizumab, by start year
YearStudies
20151
20165
201712
201829
201939
202083
202187
202247
202325
202425
202520
202620

Who runs them

Industry 51 · Other 342

Jiangsu HengRui Medicine Co., Ltd. (44) · Fudan University (29) · Sun Yat-sen University (28) · Henan Cancer Hospital (14) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (14) · Tianjin Medical University Cancer Institute and Hospital (13) · Peking Union Medical College Hospital (9) · The First Affiliated Hospital of Zhengzhou University (9)

Often tested with

Tested in the same studies.

Apatinib (111) · Famitinib (17) · Fluzoparib (14) · Paclitaxel (13) · Albumin-Bound Paclitaxel (9) · Lenvatinib (6) · Dalpiciclib (6) · Pyrotinib (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Camrelizumab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 19, 3 in phase 3

Studies that test camrelizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses camrelizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 393

See all 393 studies that test camrelizumab →

Given beside what is tested · 47 — camrelizumab is usual care or a partner of the new treatment

Showing 20 of 47.

As the comparator · 5 — what is tested is compared with camrelizumab

What changed recently

From the registry's own updates since Oct 17, 2026.

Codes

What other systems call camrelizumab · ClinicalTrials.gg INT001114

  • MeSH (NLM) C000631724camrelizumabOne source NLM
  • UNII (FDA) 73096E137ECAMRELIZUMABConfirmed FDA, NLM
  • NCI Thesaurus C123816CamrelizumabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.